BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,070 filers reported holding BAXTER INTL INC in Q3 2021. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,560,039 | +43.1% | 30,607 | +80.4% | 0.41% | -7.3% |
| Q2 2022 | $1,090,000 | -89.4% | 16,964 | -87.2% | 0.44% | -67.9% |
| Q1 2022 | $10,264,000 | +59.9% | 132,364 | +65.9% | 1.37% | +121.5% |
| Q3 2021 | $6,419,000 | +2061.3% | 79,804 | +2063.9% | 0.62% | +1371.4% |
| Q2 2021 | $297,000 | -76.2% | 3,688 | -76.2% | 0.04% | -84.4% |
| Q3 2020 | $1,247,000 | +16.3% | 15,500 | +17.4% | 0.27% | -2.2% |
| Q1 2020 | $1,072,000 | -92.1% | 13,200 | -93.6% | 0.28% | -63.7% |
| Q4 2018 | $13,562,000 | +16.4% | 206,054 | +30.6% | 0.76% | -6.2% |
| Q2 2018 | $11,654,000 | -4.7% | 157,823 | -16.1% | 0.81% | -19.5% |
| Q1 2018 | $12,229,000 | +859.1% | 188,023 | +853.3% | 1.01% | +673.8% |
| Q4 2017 | $1,275,000 | +18.1% | 19,723 | -5.3% | 0.13% | -37.8% |
| Q1 2017 | $1,080,000 | +47.1% | 20,823 | +16.6% | 0.21% | -33.0% |
| Q1 2016 | $734,000 | +42.8% | 17,861 | +32.7% | 0.31% | -10.6% |
| Q4 2015 | $514,000 | -13.3% | 13,461 | -25.5% | 0.35% | -32.4% |
| Q3 2015 | $593,000 | +56.9% | 18,061 | +81.3% | 0.52% | +15.4% |
| Q2 2015 | $378,000 | -41.4% | 9,961 | +13.7% | 0.45% | -19.7% |
| Q1 2014 | $645,000 | – | 8,761 | – | 0.56% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |